top of page

The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

FoodBev Media Logo
Nov - Food Bev - Website Banner - TIJ vs TTO 300x250.gif
Access more as a FoodBev subscriber

Sign up to FoodBev and unlock more insights from the international food and beverage industry. Subscribers have access to webinars, newsletters, publications and more...

DSM-Firmenich has unveiled Maxilact Next, which the company says is “the fastest pure lactase available on the market”. Maxilact Next enables customers to achieve a 25% reduction in hydrolysis time, producing lactose-free milk faster than its existing range of efficient Maxilact lactase enzymes. The new enzyme enables lactose-free milk producers to optimise production, increase capacity and use raw materials more efficiently – without affecting the taste of the milk-based products. Rodolfo Garza, global business development manager of milk and plant-based alternatives at DSM-Firmenich, said: “We’re proud to introduce Maxilact Next to the market – the fastest, purest, most efficient lactase enzyme solution in our portfolio yet. In the current market context, efficiency is crucial to keep up with demand and stay cost-effective. Our Maxilact range delivers optimised capacity without significant capex investment while maintaining the high quality that consumers expect.” DSM-Firmenich says that 70% of consumers worldwide are unable to properly digest lactose and that its portfolio of Maxilact enzymes provides solutions for manufacturers to optimise their raw material usage, increase yield and productivity, and maintain the highest quality standards.

FoodBev Media

FoodBev Media

2 June 2023

DSM-Firmenich expands lactase enzyme range

DSM-Firmenich expands lactase enzyme range
Related posts
DSM-Firmenich proposes Richard Ridinger as new chairman as Thomas Leysen steps down

DSM-Firmenich proposes Richard Ridinger as new chairman as Thomas Leysen steps down

Cosaic secures $6m seed funding led by DSM-Firmenich Ventures

Cosaic secures $6m seed funding led by DSM-Firmenich Ventures

DSM-Firmenich invests $10m to modernise Schenectady premix hub in the US

DSM-Firmenich invests $10m to modernise Schenectady premix hub in the US

Vivici launches fermentation-derived lactoferrin, aiming to ease supply constraints

Vivici launches fermentation-derived lactoferrin, aiming to ease supply constraints

DSM-Firmenich to sell animal nutrition unit to CVC for €2.2bn, sharpens focus on food, health and beauty

DSM-Firmenich to sell animal nutrition unit to CVC for €2.2bn, sharpens focus on food, health and beauty

DSM-Firmenich opens new global food innovation centre in Delft, the Netherlands

DSM-Firmenich opens new global food innovation centre in Delft, the Netherlands

bottom of page